ReviewJournal of family medicine and primary care2025
Bibliometric analysis of research hotspots and trends of type 2 diabetes mellitus and sodium-glucose cotransporter-2 inhibitors.
Review in Journal of family medicine and primary care, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose/background: With the rising global prevalence of type 2 diabetes mellitus (T2DM), effective treatment strategies are essential. Sodium-glucose cotransporter-2 (SGLT2) inhibitors, key in T2DM management, offer benefits beyond glycemic control. This study aimed to assess global research trends, hotspots, and future directions of SGLT2 inhibitor studies in T2DM through bibliometric analysis. Methods: English-language publications on SGLT2 inhibitors in T2DM (2014-2024) were retrieved from the Web of Science Core Collection. Bibliometric techniques were applied to analyze publication output, geographic distributions, institutional contributions, and citation patterns. Visualization and network analyses were conducted using VOSviewer (v1.6.19) and CiteSpace (v6.3.1.0). Results: A total of 4,146 publications were identified. The USA led in research output (1,152 publications), followed by Japan (857) and China (792). Annual publications grew steadily. Keyword and citation analyses revealed a shift in research focus from glycemic control to cardiovascular and renal protection. The most cited paper, Dapagliflozin and Cardiovascular Outcomes (3,842 citations), emphasized the cardiovascular benefits of SGLT2 inhibitors, reflecting the evolving "prevention-treatment integration" approach in diabetes care. Conclusions: This analysis provides a comprehensive overview of global SGLT2 inhibitor research in T2DM. The findings highlight the transition from metabolic control to cardiorenal protection, guiding future research and clinical practice.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.